SLC5A2 and systemic lupus erythematosus: Additionally, recent studies have proposed that non-immunosuppressive therapies, such as sodium-glucose cotransporter 2 inhibitors (SGLT2i), may also provide potential therapeutic value for patients with LN and other SLE comorbidities without significantly increasing the risk of HZI (92, 93).